HB002 T
Alternative Names: HB-002; HB-002T; HB002.1TLatest Information Update: 08 Jul 2023
Price :
$50 *
At a glance
- Originator Huabo Biopharm
- Class Antineoplastics; Recombinant fusion proteins
- Mechanism of Action Transforming growth factor beta1 inhibitors; Vascular endothelial growth factors inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Solid tumours
Most Recent Events
- 02 Jun 2023 Efficacy and adverse event data from phase I trial in Solid tumours presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)
- 25 Nov 2021 Phase-II clinical trials in Solid tumours (Combination therapy, In the elderly, Late-stage disease, In adults) in China (IV) (Huabo Biopharm pipeline, November 2021)
- 25 Nov 2021 Phase-II clinical trials in Solid tumours (In the elderly, Second-line therapy or greater, In adults) in China (IV) (Huabo Biopharm pipeline, November 2021)